Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age.
about
Timing of therapies for Down syndrome: the sooner, the betterThe risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyondThe gestational foundation of sex differences in development and vulnerabilityPrenatal SSRI use and offspring with autism spectrum disorder or developmental delay.Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.Antidepressant use in pregnant and postpartum womenAssociation Between Antidepressants Use During Pregnancy and Autistic Spectrum Disorders: A Meta-analysis.Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Treatment of nonpsychotic major depression during pregnancy: patient safety and challengesPsychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autismMood disorders and their pharmacological treatment during pregnancy: is the future child affected?Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatmentSelective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Placental serotonin: implications for the developmental effects of SSRIs and maternal depressionA "bottom-up" approach to aetiological research in autism spectrum disordersA prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposureThe use of central nervous system active drugs during pregnancy.Antidepressant exposure in pregnancy and risk of autism spectrum disorders.Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.Antidepressant use in pregnancy.Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy.Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.Prenatal SSRI exposure: Effects on later child development.Prenatal Antidepressant Exposure and Childhood Autism Spectrum Disorders: Cause for Concern?Use of psychotropic drugs during pregnancy and breast-feeding.The risks associated with prenatal antidepressant exposure: time for a precision medicine approach.Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database.How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring.Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort.Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study.Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database.Fine Motor Differences and Prenatal Serotonin Reuptake Inhibitors Exposure.Antenatal depression, treatment with selective serotonin reuptake inhibitors, and neonatal brain structure: A propensity-matched cohort study.A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring's outcomes.Prenatal exposure to antidepressants and language competence at age three: results from a large population-based pregnancy cohort in Norway.No association between prenatal exposure to psychotropics and intelligence at age five.Infant neurodevelopment following in utero exposure to antidepressant medication.
P2860
Q26779297-C61B40BE-A65D-4EEB-8112-F4EED7C32909Q27010327-B9192216-7469-4349-B7DC-6CF73F436793Q28385369-BA36C2A2-4528-4584-82F3-9598D4CAEEA4Q33551798-50B194AD-8A57-4993-B2D2-C9FFF1DCC3E6Q34047430-978259EA-F74B-406C-9130-32135C768985Q34068023-E8024C55-C4BC-469F-A317-5FE034424027Q34075005-32E0BDDD-4486-4660-A2A2-7120CEE7995AQ34178991-C31D48D2-56A9-4A76-8286-A8033F7B9F6AQ34237681-4A2698B3-A7B8-4F53-9AD6-1B3E28BF03B8Q34305076-36AF2E11-9106-480E-8E27-219D7FE387FEQ34895532-3ADBA2F4-A979-421C-97B6-2BF0DC96030AQ35549316-CDB3ED37-BC1C-434D-904E-230185B998FBQ35608913-4A8E5284-7F85-4710-8A0F-309D6767BC37Q36785491-41B9F4DF-4D9D-4ECC-AEE2-B7019E6EB0E6Q37182313-F644D868-25CE-47B2-83DD-760C7A0AA9AFQ37202127-515F790E-B8D2-4C30-8AC3-64A7C4AFF2EEQ37280003-18D8731C-B345-4897-B7CC-F7F84B2FF216Q37320948-04E3E58B-661C-44CE-B8EB-B9706FA0C86AQ37337705-7657ED7E-6578-4112-83C6-3F73E1A7E33EQ37577624-D846DB70-F4A6-49F8-B7A6-143B8064EC28Q37872295-20EA48C0-D310-4C79-813D-A0D5D92E1546Q37943435-3E6321C9-260A-4CE5-8620-B2F2FE6B8C26Q38089714-663430E4-6397-4254-8F38-CABC9DB7E505Q38215072-C0AB59E6-65D6-45AF-9077-7BFE4D0DC57EQ38236646-D11499F0-58F1-4E0F-8982-329E049E933DQ38532482-E1B34AFC-D01F-4CD1-9A67-175E250F7051Q38582061-24EBD028-296F-4CEA-8D24-D92FBFEFCFEEQ38722632-49EA5DAA-D7E0-47A9-B85D-5CB8DA4B1E67Q39846163-4159CE7A-DEF2-49E3-AFD1-39A30604A481Q39886560-1F2E1F1E-B51E-4ABB-85A7-6D91AC2ED88BQ40125660-AC417621-02EC-4F92-AC9C-A1106D59E606Q40535696-754EFCB7-6486-463F-A037-A787F431E586Q40535809-53D8CE3B-2C52-4DB7-B9F0-47FEACF65EDAQ40691051-AC23AF6A-0721-43B6-92B0-ADB0F94D195BQ42018860-84D04D27-C35D-4A84-AC19-73BF1A9A75B8Q42444090-A57CB62A-7F49-43E6-9B0C-8A31C7717221Q47598536-5DB8CDB9-B2E7-4286-A80D-6248015B78ADQ47889998-9284FCE7-98A2-445B-A314-49956CD60AB2Q48108567-1F026B37-16C8-43EF-9964-C65A6C7A54E8Q48439912-C09ED6F6-3AE0-4C95-A246-4D765D143D8E
P2860
Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@en
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@nl
type
label
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@en
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@nl
prefLabel
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@en
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@nl
P356
P1433
P1476
Fetal exposure to antidepressa ...... ent at 6 and 19 months of age.
@en
P2093
Tine Brink Henriksen
P304
P356
10.1542/PEDS.2008-3655
P407
P577
2010-02-22T00:00:00Z